Article Per Year (5 Year)
p-Index From 2019 - 2024
0.23
P-Index
This Author published in this journals
All Journal Journal of the Indonesian Medical Association : Majalah Kedokteran Indonesia
Hariyono Winarto
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Education Health Professions Medicine & Pharmacology Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Gambaran Myelosupresi pada pasien Kanker Ovarium yang Menerima Kemoterapi Carboplatin-Paclitaxel di RSUPN Cipto Mangunkusumo Tahun 2018 Hariyono Winarto; Andrew Wijaya
Majalah Kedokteran Indonesia Vol 70 No 4 (2020): Journal of The Indonesian Medical Association - Majalah Kedokteran Indonesia, Vo
Publisher : PENGURUS BESAR IKATAN DOKTER INDONESIA (PB IDI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47830/jinma-vol.70.4-2020-160

Abstract

Background: Ovarian cancer has the highest mortality rate among other gynecologic cancers with poor prognosis due to unspecific symptoms. Ovarian cancer is mainly treated by surgical and chemotherapy combination. Despite its curative effect chemotherapy’s, myelosuppressive is a notable side effect and may impact the next cycle of chemotherapy. This study is aimed to record laboratory changes in chemotherapy recipient in Cipto Mangunkusumo HospitalMethods: Hemoglobin, Absolute Neutrophil Count (ANC), and thrombocyte data are obtained from medical records whose received 6 cycles of Carboplatin-Paclitaxel from January-December 2018. Patients who received other chemotherapy and bone marrow metastasis were excluded.Results: Sixteen patients who completed 6 cycles were recorded. Baseline hemoglobin was 11.30±0.887 mg/dL and mean reduction was 0.29 g/dL per cycle. Mean ANC was 5,394.43±2096 cells/mm3, mean reduction was 543 cells/mm3 per cycle, and 5,35% developed neutropenia. Mean thrombocyte level was 34.225 cells/mm3 and 23% developed thrombocytopenia.Conclusions: Carboplatin-Paclitaxel’s effect on myelosuppression is prominent within the first cycle. Extra precaution must be done to prevent unwanted events.
Co-Authors Andrew Wijaya